Heterogeneity in disease risk induces falling vaccine protection with rising disease incidence
- 1 June 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in Dynamical Systems
- Vol. 32 (1), 1-22
- https://doi.org/10.1080/14689367.2016.1187115
Abstract
This paper is concerned with the analysis of phase 3 vaccine trials. In a randomized controlled trial, a representative sample of a population is given a vaccine and a matched sample is given a placebo. These individuals are followed for a stipulated length of time, while infection (or disease) occurrences are registered. Vaccine efficacy is then calculated to measure the reduction in disease rate (or risk) attributed to the vaccine. Seemingly very reasonable, this procedure often results in the most disparate estimates when conducted in different parts of the world. Here, we argue that this is due to cohort selection acting on the trial participants as follows. The more susceptible individuals are infected first, leaving behind a pool whose mean susceptibility decreases over time. As a result, infection rates decrease, and this effect is stronger in the control group, provided that the vaccine reduces susceptibility. Therefore, any direct measure of vaccine efficacy is expected to decrease as the trial progresses, and this happens faster in settings where the intensity of pathogen exposure is higher. We propose an analytical scheme that takes this phenomenon into account while estimating efficacy more consistently across settings. We provide analytical results concerning the dependence of vaccine efficacy on the intensity of pathogen exposure as well as on the mean and variance of the distribution of disease risk.Keywords
This publication has 13 references indexed in Scilit:
- Estimating the Per-Exposure Effect of Infectious Disease InterventionsEpidemiology, 2014
- Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled TrialsClinical Infectious Diseases, 2013
- Model hierarchies in edge-based compartmental modeling for infectious disease spreadJournal of Mathematical Biology, 2012
- How host heterogeneity governs tuberculosis reinfection?Proceedings. Biological sciences, 2012
- Apparent declining efficacy in randomized trialsAIDS, 2012
- Performance of rotavirus vaccines in developed and developing countriesHuman Vaccines, 2010
- Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trialsMalaria Journal, 2010
- The entomological inoculation rate and Plasmodium falciparum infection in African childrenNature, 2005
- Heterogeneity's Ruses: Some Surprising Effects of Selection on Population DynamicsThe American Statistician, 1985
- Assessment of the Protective Efficacy of Vaccines against Common Diseases Using Case-Control and Cohort StudiesInternational Journal of Epidemiology, 1984